Previous 10 | Next 10 |
home / stock / cvalf / cvalf news
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2023 results. Brian Pedlar, Covalon’s President and CEO, said, “I am pleased to announce another strong financial ...
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2023 financial results on Wednesday, August 16, 2023, before markets open. A conference call and webcast to discuss the financial results will be ...
New Journal of Association for Vascular Access publication featuring VALGuard offers health care professionals Continuing Education Credits as it contributes to their professional development Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced m...
Visit booth 307 to learn how Covalon is creating a new standard for compassionate IV care technology designed to help protect patients from infections, pain, and trauma Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies com...
Visit booth 612 to discover how Covalon is setting new standards in compassionate innovation for infection prevention solutions that deliver tough protection with gentle care Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologi...
Registration now open: Save patient skin and stop cringeworthy dressing trauma Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced an expert-led webinar titled “Addressing MARSI in Vascular Ac...
Anesthesiologists recommend Covalon’s gentle and effective silicone solution over acrylic dressings for securing vascular insertion sites in Epidermolysis Bullosa patients prone to skin injury Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an ad...
2023-05-25 09:14:05 ET Covalon Technologies press release ( OTCQX:CVALF ): Q2 GAAP EPS of -$0.03. Revenue of $7.2M (+118.8% Y/Y). For further details see: Covalon Technologies GAAP EPS of -$0.03, revenue of $7.2M
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its second quarter fiscal 2023 results. Brian Pedlar, Covalon’s President and CEO, said, “I am pleased to announce another strong financial...
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2023 financial results on Thursday, May 25, 2023, before markets open. A conference call and webcast to discuss the financial results will be held...
News, Short Squeeze, Breakout and More Instantly...
Recent changes and effective execution pave the way for strong Q2 results Q2 EBITDA of $1.7 million, Adjusted EBITDA of $2.5 million, and EPS of $0.06 Q2 year-on-year Revenue growth of 16%, focus area of US Product segment grew 54% Q2 Gross Margin increased to 63%, the h...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...
Covalon Technologies Ltd. (CVALF) is expected to report for Q2 2024